Pharmacokinetics

Pharmacokinetics (from Ancient Greek pharmakon 'drug' and kinetikos 'moving, putting in motion'; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to describing how the body affects a specific…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 6 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Pharmacokinetics (from Ancient Greek pharmakon 'drug' and kinetikos 'moving, putting in motion'; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to describing how the body affects a specific substance after administration. The substances of interest include any chemical xenobiotics such as pharmaceutical drugs, pesticides, food additives, cosmetics, etc. PK attempts to analyze chemical metabolism and discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body.

PK is based on mathematical modeling that places great emphasis on the relationship between drug plasma concentration and the time elapsed since the drug's administration. Pharmacokinetics is the study of how an organism affects the drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism.

Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models. In pharmacokinetics, steady state refers to the situation where the overall intake of a drug is fairly in dynamic equilibrium with its elimination. In practice, it is generally considered that once regular dosing of a drug is started, steady state is reached after 3 to 5 times its half-life.

In steady state and in linear pharmacokinetics, AUC τ =AUC ∞ . In this one-compartment model, the most common model of elimination is first order kinetics, where the elimination of the drug is directly proportional to the drug's concentration in the organism.

This is often called linear pharmacokinetics, as the change in concentration over time can be expressed as a linear differential equation \frac{dC}{dt} = -k_\text{el} C . Assuming a single IV bolus dose resulting in a concentration C_\text{initial} at time t=0 , the equation can be solved to give C=C_\text{initial} \times e^{-k_\text{el} \times t} . Vd_F = Vd_{T1} + Vd_{T2} + Vd_{T3} + \cdots + Vd_{Tn}\, This represents the multi-compartment model with a number of curves that express complicated equations in order to obtain an overall curve.

A number of computer programs have been developed to plot these equations. The most complex PK models (called PBPK models) rely on the use of physiological information to ease development and validation.

The graph for the non-linear relationship between the various factors is represented by a curve; the relationships between the factors can then be found by calculating the dimensions of different areas under the curve. The models used in non-linear pharmacokinetics are largely based on Michaelis–Menten kinetics.

A reaction's factors of non-linearity include the following: Multiphasic absorption: Drugs injected intravenously are removed from the plasma through two primary mechanisms: (1) Distribution to body tissues and (2) metabolism + excretion of the drugs. The resulting decrease of the drug's plasma concentration follows a biphasic pattern (see figure).

Alpha phase: An initial phase of rapid decrease in plasma concentration. The decrease is primarily attributed to drug distribution from the central compartment (circulation) into the peripheral compartments (body tissues). This phase ends when a pseudo-equilibrium of drug concentration is established between the central and peripheral compartments.

Beta phase: A phase of gradual decrease in plasma concentration after the alpha phase. The decrease is primarily attributed to drug elimination, that is, metabolism and excretion. Additional phases (gamma, delta, etc.) are sometimes seen.

A drug's characteristics make a clear distinction between tissues with high and low blood flow. Enzymatic saturation: When the dose of a drug whose elimination depends on biotransformation is increased above a certain threshold the enzymes responsible for its metabolism become saturated.

The drug's plasma concentration will then increase disproportionately and its elimination will no longer be constant. Induction or enzymatic inhibition: Some drugs have the capacity to inhibit or stimulate their own metabolism, in negative or positive feedback reactions (e.g. this occurs with fluvoxamine, fluoxetine and phenytoin).

As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required. The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations.

It can therefore be seen that non-linearity can occur because of reasons that affect the entire pharmacokinetic sequence: absorption, distribution, metabolism and elimination. B_A = \frac{[ABC]_P \cdot D_{IV}}{[ABC]_{IV} \cdot D_P} \mathit B_R = \frac{[ABC]_A \cdot \text{dose}_B}{[ABC]_B \cdot \text{dose}_A} Once a drug's bioavailability has been established it is possible to calculate the changes that need to be made to its dosage in order to reach the required blood plasma levels.

Bioavailability is, therefore, a mathematical factor for each individual drug that influences the administered dose. It is possible to calculate the amount of a drug in the blood plasma that has a real potential to bring about its effect using the formula: De = B \cdot Da\, where De is the effective dose, B bioavailability and Da the administered dose.

Therefore, if a drug has a bioavailability of 0.8 (or 80%) and it is administered in a dose of 100 mg, the equation will demonstrate the following: De = 0.8 × 100 mg = 80 mg That is the 100 mg administered represents a blood plasma concentration of 80 mg that has the capacity to have a pharmaceutical effect. This concept depends on a series of factors inherent to each drug, such as: Pharmaceutical form Chemical form Route of administration Stability Metabolism These concepts, which are discussed in detail in their respective titled articles, can be mathematically quantified and integrated to obtain an overall mathematical equation: De = Q\cdot Da\cdot B\, where Q is the drug's purity.

Va = \frac{Da \cdot B \cdot Q} \tau where Va is the drug's rate of administration and \tau is the rate at which the absorbed drug reaches the circulatory system. Finally, using the Henderson-Hasselbalch equation, and knowing the drug's pKa\, (pH at which there is an equilibrium between its ionized and non-ionized molecules), it is possible to calculate the non-ionized concentration of the drug and therefore the concentration that will be subject to absorption: \mathrm{pH} = \mathrm{pKa} + \log \frac B A When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents.

The concept of bioequivalence is important since it is currently used as a yardstick in the authorization of generic drugs in many countries.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1373279536 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

12 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.